Cargando…
A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy
BACKGROUND: HIV-1-related inflammation is associated with increased levels of biomarkers of vascular adhesion and endothelial activation, and may increase production of the inflammatory protein angiopoietin-2 (ANG-2), an adverse prognostic biomarker in severe systemic infection. We hypothesized that...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3679794/ https://www.ncbi.nlm.nih.gov/pubmed/23734875 http://dx.doi.org/10.1186/1471-2334-13-263 |
_version_ | 1782273018091798528 |
---|---|
author | Graham, Susan M Rajwans, Nimerta Tapia, Kenneth A Jaoko, Walter Estambale, Benson BA McClelland, R Scott Overbaugh, Julie Liles, W Conrad |
author_facet | Graham, Susan M Rajwans, Nimerta Tapia, Kenneth A Jaoko, Walter Estambale, Benson BA McClelland, R Scott Overbaugh, Julie Liles, W Conrad |
author_sort | Graham, Susan M |
collection | PubMed |
description | BACKGROUND: HIV-1-related inflammation is associated with increased levels of biomarkers of vascular adhesion and endothelial activation, and may increase production of the inflammatory protein angiopoietin-2 (ANG-2), an adverse prognostic biomarker in severe systemic infection. We hypothesized that antiretroviral therapy (ART) initiation would decrease endothelial activation, reducing plasma levels of ANG-2. METHODS: Antiretroviral-naïve Kenyan women with advanced HIV infection were followed prospectively. Endothelial activation biomarkers including soluble intercellular adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1), and E-selectin, and plasma ANG-2 and angiopoietin-1 (ANG-1) were tested in stored plasma samples from 0, 6, and 12 months after ART initiation. We used Wilcoxon matched-pairs signed rank tests to compare endothelial activation biomarkers across time-points, generalized estimating equations to analyze associations with change in log(10)-transformed biomarkers after ART initiation, and Cox proportional-hazards regression to analyze associations with mortality. RESULTS: The 102 HIV-1-seropositive women studied had advanced infection (median CD4 count, 124 cells/μL). Soluble ICAM-1 and plasma ANG-2 levels decreased at both time-points after ART initiation, with concomitant increases in the beneficial protein ANG-1. Higher ANG-2 levels after ART initiation were associated with higher plasma HIV-1 RNA, oral contraceptive pill use, pregnancy, severe malnutrition, and tuberculosis. Baseline ANG-2 levels were higher among five women who died after ART initiation than among women who did not (median 2.85 ng/mL [inter-quartile range (IQR) 2.47–5.74 ng/mL] versus median 1.32 ng/mL [IQR 0.35–2.18 ng/mL], p = 0.01). Both soluble ICAM-1 and plasma ANG-2 levels predicted mortality after ART initiation. CONCLUSIONS: Biomarkers of endothelial activation decreased after ART initiation in women with advanced HIV-1 infection. Changes in plasma ANG-2 were associated with HIV-1 RNA levels over 12 months of follow-up. Soluble ICAM-1 and plasma ANG-2 levels represent potential biomarkers for adverse outcomes in advanced HIV-1 infection. |
format | Online Article Text |
id | pubmed-3679794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-36797942013-06-13 A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy Graham, Susan M Rajwans, Nimerta Tapia, Kenneth A Jaoko, Walter Estambale, Benson BA McClelland, R Scott Overbaugh, Julie Liles, W Conrad BMC Infect Dis Research Article BACKGROUND: HIV-1-related inflammation is associated with increased levels of biomarkers of vascular adhesion and endothelial activation, and may increase production of the inflammatory protein angiopoietin-2 (ANG-2), an adverse prognostic biomarker in severe systemic infection. We hypothesized that antiretroviral therapy (ART) initiation would decrease endothelial activation, reducing plasma levels of ANG-2. METHODS: Antiretroviral-naïve Kenyan women with advanced HIV infection were followed prospectively. Endothelial activation biomarkers including soluble intercellular adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1), and E-selectin, and plasma ANG-2 and angiopoietin-1 (ANG-1) were tested in stored plasma samples from 0, 6, and 12 months after ART initiation. We used Wilcoxon matched-pairs signed rank tests to compare endothelial activation biomarkers across time-points, generalized estimating equations to analyze associations with change in log(10)-transformed biomarkers after ART initiation, and Cox proportional-hazards regression to analyze associations with mortality. RESULTS: The 102 HIV-1-seropositive women studied had advanced infection (median CD4 count, 124 cells/μL). Soluble ICAM-1 and plasma ANG-2 levels decreased at both time-points after ART initiation, with concomitant increases in the beneficial protein ANG-1. Higher ANG-2 levels after ART initiation were associated with higher plasma HIV-1 RNA, oral contraceptive pill use, pregnancy, severe malnutrition, and tuberculosis. Baseline ANG-2 levels were higher among five women who died after ART initiation than among women who did not (median 2.85 ng/mL [inter-quartile range (IQR) 2.47–5.74 ng/mL] versus median 1.32 ng/mL [IQR 0.35–2.18 ng/mL], p = 0.01). Both soluble ICAM-1 and plasma ANG-2 levels predicted mortality after ART initiation. CONCLUSIONS: Biomarkers of endothelial activation decreased after ART initiation in women with advanced HIV-1 infection. Changes in plasma ANG-2 were associated with HIV-1 RNA levels over 12 months of follow-up. Soluble ICAM-1 and plasma ANG-2 levels represent potential biomarkers for adverse outcomes in advanced HIV-1 infection. BioMed Central 2013-06-04 /pmc/articles/PMC3679794/ /pubmed/23734875 http://dx.doi.org/10.1186/1471-2334-13-263 Text en Copyright © 2013 Graham et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Graham, Susan M Rajwans, Nimerta Tapia, Kenneth A Jaoko, Walter Estambale, Benson BA McClelland, R Scott Overbaugh, Julie Liles, W Conrad A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy |
title | A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy |
title_full | A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy |
title_fullStr | A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy |
title_full_unstemmed | A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy |
title_short | A prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women initiating antiretroviral therapy |
title_sort | prospective study of endothelial activation biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in kenyan women initiating antiretroviral therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3679794/ https://www.ncbi.nlm.nih.gov/pubmed/23734875 http://dx.doi.org/10.1186/1471-2334-13-263 |
work_keys_str_mv | AT grahamsusanm aprospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy AT rajwansnimerta aprospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy AT tapiakennetha aprospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy AT jaokowalter aprospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy AT estambalebensonba aprospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy AT mcclellandrscott aprospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy AT overbaughjulie aprospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy AT lileswconrad aprospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy AT grahamsusanm prospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy AT rajwansnimerta prospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy AT tapiakennetha prospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy AT jaokowalter prospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy AT estambalebensonba prospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy AT mcclellandrscott prospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy AT overbaughjulie prospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy AT lileswconrad prospectivestudyofendothelialactivationbiomarkersincludingplasmaangiopoietin1andangiopoietin2inkenyanwomeninitiatingantiretroviraltherapy |